Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMLA: R2-MTX and Lenalidomide Maintenance for PCNSL
NCT04120350Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in primary central nervous system lymphoma (PCNSL), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04120350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120350.